The global pyelonephritis drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). A kidney infection, commonly known as pyelonephritis, is a form of urinary tract infection characterized by inflammation of one or both kidneys. Bacteria or a virus causes the illness, which usually starts in the urinary bladder and spreads to one or both kidneys. Confusion and back pain, chills and high fever, nausea and vomiting, back, side, and groyne discomfort, and painful urination are all signs or symptoms of pyelonephritis, which might vary based on age. Kidney stones, a weaker immune system, anatomical abnormalities with the urinary tract, urine reflux issues, and nerve damage surrounding the bladder are all some factors that cause pyelonephritis. Owing to the high prevalence and incidence rates of pyelonephritis problems around the world, the global pyelonephritis treatment market is expected to rise rapidly during the forecast period. Each year, over 200,000 hospitalizations for acute pyelonephritis are reported in the US. As a result, the global pyelonephritis treatment market is likely to be driven by a huge population base with a kidney infection during the forecast period.

The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, in October 2021, Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases, announced that it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for approval of tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis, caused by susceptible microorganisms. 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Product Type
• By Application

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Merck & Co, Inc., and AstraZeneca plc, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pyelonephritis Drug Market Report by Segment

By Product Type

• Finafloxacin
• Fosfomycin Tromethamine
• Nacubactam
• Plazomicin Sulfate
• Others

By Application

• Hospital
• Clinic
• Others

Global Pyelonephritis Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific 

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa